The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 03, 2023

Filed:

Aug. 28, 2019
Applicant:

Cormedix Inc., Berkeley Heights, NJ (US);

Inventors:

Bruce Reidenberg, Rye, NY (US);

Robert DiLuccio, Viera, FL (US);

Assignee:

CorMedix Inc., Berkeley Heights, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/549 (2006.01); A61K 31/18 (2006.01); A61K 31/047 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 47/34 (2017.01);
U.S. Cl.
CPC ...
A61K 31/549 (2013.01); A61K 9/0019 (2013.01); A61K 9/14 (2013.01); A61K 31/047 (2013.01); A61K 31/18 (2013.01); A61K 47/34 (2013.01);
Abstract

Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. The efficacy in rodent model is superior to the efficacy in cell culture. This invention relates to the use of taurolidine hydrolysis products (tarultam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in juvenile mammals.


Find Patent Forward Citations

Loading…